Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Bruce Ren
 + 600 word(s) 600 2020-12-15 07:38:55 |
2 format correct
Bruce Ren
 + 12 word(s) 612 2020-12-23 07:00:15 | |
3 format correct
Bruce Ren
 + 12 word(s) 612 2020-12-23 07:00:31 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Ren, B. SMARD1. Encyclopedia. Available online: https://encyclopedia.pub/entry/3825 (accessed on 26 December 2024).
Ren B. SMARD1. Encyclopedia. Available at: https://encyclopedia.pub/entry/3825. Accessed December 26, 2024.
Ren, Bruce. "SMARD1" Encyclopedia, https://encyclopedia.pub/entry/3825 (accessed December 26, 2024).
Ren, B. (2020, December 22). SMARD1. In Encyclopedia. https://encyclopedia.pub/entry/3825
Ren, Bruce. "SMARD1." Encyclopedia. Web. 22 December, 2020.
SMARD1
Edit
This entry is adapted from the peer-reviewed paper https://medlineplus.gov/genetics/condition/spinal-muscular-atrophy-with-respiratory-distress-type-1

Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is an inherited condition that causes muscle weakness and respiratory failure typically beginning in infancy.

genetic conditions

1. Introduction

Spinal muscular atrophy with respiratory distress type 1 (SMARD1) is an inherited condition that causes muscle weakness and respiratory failure typically beginning in infancy. Early features of this condition are difficult and noisy breathing, especially when inhaling; a weak cry; problems feeding; and recurrent episodes of pneumonia. Typically between the ages of 6 weeks and 6 months, infants with this condition will experience a sudden inability to breathe due to paralysis of the muscle that separates the abdomen from the chest cavity (the diaphragm). Normally, the diaphragm contracts and moves downward during inhalation to allow the lungs to expand. With diaphragm paralysis, affected individuals require life-long support with a machine to help them breathe (mechanical ventilation). Rarely, children with SMARD1 develop signs or symptoms of the disorder later in childhood.

Soon after respiratory failure occurs, individuals with SMARD1 develop muscle weakness in their distal muscles. These are the muscles farther from the center of the body, such as muscles in the hands and feet. The weakness soon spreads to all muscles; however, within 2 years, the muscle weakness typically stops getting worse. Some individuals may retain a low level of muscle function, while others lose all ability to move their muscles. Muscle weakness severely impairs motor development, such as sitting, standing, and walking. Some affected children develop an abnormal side-to-side and back-to-front curvature of the spine (scoliosis and kyphosis, often called kyphoscoliosis when they occur together). After approximately the first year of life, individuals with SMARD1 may lose their deep tendon reflexes, such as the reflex being tested when a doctor taps the knee with a hammer.

Other features of SMARD1 can include reduced pain sensitivity, excessive sweating (hyperhidrosis), loss of bladder and bowel control, and an irregular heartbeat (arrhythmia).

2. Frequency

SMARD1 appears to be a rare condition, but its prevalence is unknown. More than 60 cases have been reported in the scientific literature.

3. Causes

Mutations in the IGHMBP2 gene cause SMARD1. The IGHMBP2 gene provides instructions for making a protein involved in copying (replicating) DNA; producing RNA, a chemical cousin of DNA; and producing proteins. IGHMBP2 gene mutations that cause SMARD1 lead to the production of a protein with reduced ability to aid in DNA replication and the production of RNA and proteins. These problems particularly affect alpha-motor neurons, which are specialized cells in the brainstem and spinal cord that control muscle movements. Although the mechanism is unknown, altered IGHMBP2 proteins contribute to the damage of these neurons and their death over time. The cumulative death of alpha-motor neurons leads to breathing problems and progressive muscle weakness in children with SMARD1.

Research suggests that the amount of functional protein that is produced from the mutated IGHMBP2 gene may play a role in the severity of SMARD1. Individuals who have some functional protein are more likely to develop signs and symptoms later in childhood and retain a greater level of muscle function.

3.1 The gene associated with Spinal muscular atrophy with respiratory distress type 1

4. Inheritance

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

5. Other Names for This Condition

  • autosomal recessive distal spinal muscular atrophy 1
  • DHMN6
  • diaphragmatic spinal muscular atrophy
  • distal hereditary motor neuronopathy type VI
  • distal spinal muscular atrophy type 1
  • DSMA1
  • HMN6
  • HMNVI
  • severe infantile axonal neuropathy with respiratory failure
  • SIANRF
  • SMARD1
  • spinal muscular atrophy with respiratory distress

References

  1. Eckart M, Guenther UP, Idkowiak J, Varon R, Grolle B, Boffi P, Van MaldergemL, Hübner C, Schuelke M, von Au K. The natural course of infantile spinalmuscular atrophy with respiratory distress type 1 (SMARD1). Pediatrics. 2012Jan;129(1):e148-56. doi: 10.1542/peds.2011-0544.
  2. Guenther UP, Handoko L, Varon R, Stephani U, Tsao CY, Mendell JR, Lützkendorf S, Hübner C, von Au K, Jablonka S, Dittmar G, Heinemann U, Schuetz A, Schuelke M.Clinical variability in distal spinal muscular atrophy type 1 (DSMA1):determination of steady-state IGHMBP2 protein levels in five patients withinfantile and juvenile disease. J Mol Med (Berl). 2009 Jan;87(1):31-41. doi:10.1007/s00109-008-0402-7.
  3. Guenther UP, Varon R, Schlicke M, Dutrannoy V, Volk A, Hübner C, von Au K,Schuelke M. Clinical and mutational profile in spinal muscular atrophy withrespiratory distress (SMARD): defining novel phenotypes through hierarchicalcluster analysis. Hum Mutat. 2007 Aug;28(8):808-15.
  4. Kaindl AM, Guenther UP, Rudnik-Schöneborn S, Varon R, Zerres K, Schuelke M,Hübner C, von Au K. Spinal muscular atrophy with respiratory distress type 1(SMARD1). J Child Neurol. 2008 Feb;23(2):199-204. doi: 10.1177/0883073807310989.
  5. van der Pol WL, Talim B, Pitt M, von Au K. 190 th ENMC international workshop:Spinal muscular atrophy with respiratory distress/distal spinal muscular atrophy type 1: 11-13 May 2012, Naarden, The Netherlands. Neuromuscul Disord. 2013Jul;23(7):602-9. doi: 10.1016/j.nmd.2013.04.004.
More
©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Genetics & Heredity
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Bruce Ren
View Times: 573
Entry Collection: MedlinePlus
Revisions: 3 times (View History)
Update Date: 23 Dec 2020
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback